BioNexus Gene Lab Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Cash & Equivalents	1.34	2.38	1.58	2.62	0.61
Short-Term Investments	2.63	1.66	2.79	3.31	1.51
Cash & Short-Term Investments	3.96	4.04	4.38	5.93	2.12
Cash Growth	10.28%	-7.71%	-26.17%	179.84%	-
Accounts Receivable	0.08	0.51	1.38	0.8	2.87
Other Receivables	0.09	0.08	0.2	0.12	0.03
Total Trade Receivables	0.17	0.59	1.58	0.92	2.89
Inventory	0.67	0.68	1.39	1.14	0.98
Other Current Assets	0.39	0.14	0.08	0.06	0.03
Total Current Assets	5.2	5.45	7.43	8.05	6.02
Net Property, Plant & Equipment	1.82	1.78	1.74	1.65	1.57
Long-Term Investments	2.03	2.03	1.27	1.7	1.15
Total Assets	9.04	9.25	10.43	11.4	8.74
Accounts Payable	0	0	1.5	1.4	1.86
Accrued Expenses	0.59	0.4	0.28	0.18	0.1
Current Portion of Leases	0.07	0.06	0.05	0.03	0.02
Unearned Revenue	0.01	0.01	0.1	-	0.02
Other Current Liabilities	0.13	0.05	0.02	0.01	-
Total Current Liabilities	0.8	0.52	1.95	1.63	2
Long-Term Leases	0.15	0.12	0.16	0.1	0.04
Other Long-Term Liabilities	-	-	-	0.01	0.03
Total Long-Term Liabilities	0.15	0.12	0.16	0.11	0.07
Total Liabilities	0.95	0.64	2.11	1.74	2.08
Common Stock	20.17	20.17	17.33	17.19	10.93
Additional Paid-in Capital	-5.01	-5.01	-5.01	-5.01	-5.01
Accumulated Other Comprehensive Income	-0.1	-0.12	-0.56	-0.68	-0.41
Retained Earnings	-6.97	-6.43	-3.44	-1.84	1.16
Shareholders' Equity	8.09	8.61	8.32	9.66	6.67
Total Liabilities & Equity	9.04	9.25	10.43	11.4	8.74
Total Debt	0.22	0.18	0.21	0.13	0.06
Net Cash (Debt)	3.75	3.86	4.17	5.8	2.06
Net Cash Growth	-2.98%	-7.28%	-28.11%	181.07%	-
Net Cash Per Share	1.86	2.08	2.34	4.02	1.43
Book Value	8.09	8.61	8.32	9.66	6.67
Book Value Per Share	4.02	4.64	4.67	6.70	4.63
Tangible Book Value	8.09	8.61	8.32	9.66	6.67
Tangible Book Value Per Share	4.02	4.64	4.67	6.70	4.63

SEC Filings: 10-K · 10-Q